[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

COVID-19 Saliva Screening Test Potential Market Size, Share & Trends Analysis Report By Location (Travel Stations), By Technology, By Mode (Centralized Testing, Decentralized Testing), By Region, And Segment Forecasts, 2021 - 2023

June 2021 | 178 pages | ID: C327DE258C7CEN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 72 Business Hours

COVID-19 Saliva Screening Test Potential Market Growth & Trends

The global COVID-19 saliva screening test potential market size is expected to reach USD 3,406.2 billion by 2023, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 4.8% from 2021 to 2023. The rise in demand for rapid, efficient, saliva-based screening tests has positively impacted market growth.

This is primarily due to the various advantages offered by saliva-based tests, increasing product approvals by regulatory bodies, and a paradigm shift toward point-of-care testing. The fluorescence-labeled antigen/antibodies test is one of the recent saliva-based COVID-19 screening tests in the market which is based on the principles of fluorescence detection, biochemistry, robotics automation, and cloud computing.

As the number of people visiting public places is increasing and reaching pre-pandemic statistics in a few countries, there is a growing demand for rapid, point-of-care COVID-19 tests to mitigate viral transmission from asymptomatic people. This has enhanced the R&D for the development of simple yet effective saliva-based tests and is expected to create lucrative opportunities for several developers.

COVID-19 Saliva Screening Test Potential Market Report Highlights
  • The market estimates represent a potential market size for the COVID-19 saliva screening test based on the assumptions that the end-use locations have a 60% population attendance or capacity (60% of pre-COVID attendance) and the testing rate using test device is 100%
  • Saliva-based tests play a vital role in screening asymptomatic individuals thereby aiding in market revenue generation in the near future
  • The fluorescence-labeled antigen/antibodies test is designed to accelerate rapid point-of-access testing of individuals
  • Owing to the pandemic, the economy across the various sectors is severely impacted.
  • However, with the reopening of various sectors and locations such as shopping malls and amusement parks, there is a growing need for screening individuals to curb viral transmission
  • In the U.S., more than 40 amusement parks have prepared to reopen by the spring of 2021, thus increasing the demand for rapid tests
  • Thus, there is a high growth potential for the market with the increase in usage of the medical test at various locations to screen individuals
  • Regulatory bodies such as the U.S. FDA and European Medicine Agency (EMA) have supported these products by providing EUA and product approvals
  • In April 2021, Vatic Health received the CE mark for its on-the-spot’ saliva antigen test for the SARS-CoV-2 virus. The test has also completed the Medicines and Healthcare Products Regulatory Agency (MHRA) registration in the U.K.
  • North America dominated the market owing to the high penetration and adoption of saliva-based screening tests in the region
  • The U.S. is the major contributor to revenue generation due to the emergence of new small and mid-sized companies engaged in the development of such tests
CHAPTER 1 METHODOLOGY AND SCOPE

1.1 Research Scope
  1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
  1.3.1 Purchased database
  1.3.2 GVR’s internal database
  1.3.3 Secondary sources
    1.3.3.1 List of secondary data sources
  1.3.4 Primary research
1.4 Information or Data Analysis
  1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Market Model
1.7 Model Details
  1.7.1 Location scope
    1.7.1.1 Travel stations
      1.7.1.1.1 Airports
      1.7.1.1.2 Ports & Cruise
      1.7.1.1.3 Train Stations
      1.7.1.1.4 Border crossings
    1.7.1.2 Sports arenas
    1.7.1.3 Entertainment venues
    1.7.1.4 Universities & Colleges
    1.7.1.5 Corporate Campus Environments and Factories
  1.7.2 Technology scope
    1.7.2.1 FDA recommendations for the use of diagnostic tests for screening
  1.7.3 Region-wise market: Base estimates
1.8 Objectives
  1.8.1 Objective 1:
  1.8.2 Objective 2:

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Outlook
2.2 Segment Outlook
2.3 Market Summary

CHAPTER 3 COVID-19 SALIVA SCREENING TEST POTENTIAL MARKET: INDUSTRY OUTLOOK

3.1 Fluorescence-labeled antigen/antibodies testing: Opportunity Analysis
  3.1.1 Competitive products analysis
    3.1.1.1 Competitive analysis- COVID-19 POC testing
3.2 Market Dynamics
  3.2.1 Market driver analysis
    3.2.1.1 Advantages of using saliva as a diagnostic specimen
    3.2.1.2 Increasing product approvals by regulatory agencies
    3.2.1.3 Paradigm shift toward point-of-care testing
  3.2.2 Market restraint analysis
    3.2.2.1 High penetration of swab-based testing methods
    3.2.2.2 Limitations related to the methodological approach
  3.2.3 Market opportunity analysis
    3.2.3.1 Safe, quick, and economical nature of saliva-based COVID-19 tests
  3.2.4 Market challenge analysis
    3.2.4.1 Challenges pertaining to COVID-19 testing in healthcare settings
3.3 Comparative Analysis
  3.3.1 Saliva testing versus swab-based RT-PCR testing
    3.3.1.1 Global swab-based COVID-19 Diagnostics market, 2020 – 2027 (USD Million)
  3.3.2 Saliva testing versus other antigen testing
3.4 Competitive Analysis
  3.4.1 Major deals &strategic alliances analysis
    3.4.1.1 Technology collaboration & licensing partnership
    3.4.1.2 Distribution partnership
  3.4.2 Strategy framework
  3.4.3 Company participant categorization
  3.4.4 Product approval/EUA authorizations& launch timeline

CHAPTER 4 COVID-19 SALIVA SCREENING TEST POTENTIAL MARKET: LOCATION ESTIMATES & TREND ANALYSIS (U.S. & CANADA)

4.1 Travel Stations
  4.1.1 Airports
  4.1.2 Cruise
  4.1.3 Port
  4.1.4 Train stations
  4.1.5 Border crossing
4.2 Sports Arenas
4.3 Concert Halls
4.4 Shopping Malls and Centers
4.5 Amusement Parks
4.6 Corporate Campus Environment
4.7 Universities and Colleges
4.8 Factories
  4.8.1 Food processing plants
  4.8.2 Meat packing plants
  4.8.3 Pharmaceutical plants
  4.8.4 Mining
  4.8.5 Retail working warehouses

CHAPTER 5 COVID-19 SALIVA SCREENING TEST POTENTIAL MARKET: LOCATION ESTIMATES & TREND ANALYSIS (OTHER REGIONS)

5.1 Travel Stations
5.2 Sport Arenas
5.3 Entertainment Venues
5.4 Corporate Environments
5.5 Universities & Colleges
5.6 Factories

CHAPTER 6 COVID-19 SALIVA SCREENING TEST POTENTIAL MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS

6.1 COVID-19 Saliva Screening Market: Technology Movement Analysis
6.2 Fluorescence-labeled antigen/antibodies testing
  6.2.1 Overview
  6.2.2 Key strategic intiatives
6.3 RT-PCR
  6.3.1 Technical viewpoint
  6.3.2 Future potential
  6.3.3 Commercial viewpoint
6.4 CRISPR-Cas9
  6.4.1 Technical viewpoint
  6.4.2 Future potential
  6.4.3 Commercial viewpoint

CHAPTER 7 COVID-19 SALIVA SCREENING TEST POTENTIAL MARKET: MODE ESTIMATES & TREND ANALYSIS

7.1 COVID-19 Saliva Screening Test Potential Market: Mode Movement Analysis
7.2 Centralized Testing (Labs, Hospitals, Clinics)
7.3 Decentralized Testing (Mobile Testing, At-home Testing, Others)

CHAPTER 8 REGIONAL BUSINESS ANALYSIS

8.1 COVID-19 Saliva Screening Test Potential Market: Regional Movement Analysis, 2020 & 2023
8.2 North America
  8.2.1 U.S.
  8.2.2 Canada
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World

CHAPTER 9 COMPANY PROFILES

9.1 Company Profiles
  9.1.1 ARUP Laboratories.
    9.1.1.1 Company overview
    9.1.1.2 Financial performance
    9.1.1.3 Product benchmarking
    9.1.1.4 Strategic initiatives
  9.1.2 Vatic Health
    9.1.2.1 Company overview
    9.1.2.2 Product benchmarking
    9.1.2.3 Strategic initiatives
  9.1.3 MOgene
    9.1.3.1 Company overview
    9.1.3.2 Financial performance
    9.1.3.3 Product benchmarking
    9.1.3.4 Strategic initiatives
  9.1.4 Psomagen, INC.
    9.1.4.1 Company overview
    9.1.4.2 Financial performance
    9.1.4.3 Product benchmarking
    9.1.4.4 Strategic initiatives
  9.1.5 DXTERITY Diagnostics, INC.
    9.1.5.1 Company overview
    9.1.5.2 Financial performance
    9.1.5.3 Product benchmarking
    9.1.5.4 Strategic initiatives
  9.1.6 KONICA MINOLTA, INC.
    9.1.6.1 Company overview
    9.1.6.2 Ambry Genetics
      9.1.6.2.1 Company overview
    9.1.6.3 Financial performance
      9.1.6.3.1 Financial performance
    9.1.6.4 Product benchmarking
    9.1.6.5 Strategic initiatives
  9.1.7 Fluidigm Corporation
    9.1.7.1 Company overview
    9.1.7.2 Financial performance
    9.1.7.3 Product benchmarking
    9.1.7.4 Strategic initiatives
  9.1.8 Phosphorus Diagnostics LLC
    9.1.8.1 Company overview
    9.1.8.2 Product benchmarking
    9.1.8.3 Strategic initiatives
  9.1.9 Gravity Diagnostics
    9.1.9.1 Company overview
    9.1.9.2 Product benchmarking
    9.1.9.3 Strategic initiatives
  9.1.10 OraSure Technologies
    9.1.10.1 Company overview
    9.1.10.2 DNA Genotek, Inc.
      9.1.10.2.1 Company overview
    9.1.10.3 Financial performance
      9.1.10.3.1 Financial performance
    9.1.10.4 Product benchmarking
    9.1.10.5 Strategic initiatives
  9.1.11 Quidel Corporation
    9.1.11.1 Company overview
    9.1.11.2 Financial performance
    9.1.11.3 Product benchmarking
    9.1.11.4 Strategic initiatives
  9.1.12 ABBOTT
    9.1.12.1 Company overview
    9.1.12.2 Financial performance
    9.1.12.3 Product benchmarking
    9.1.12.4 Strategic initiatives
  9.1.13 LumiraDX
    9.1.13.1 Company overview
    9.1.13.2 Financial performance
    9.1.13.3 Product benchmarking
    9.1.13.4 Strategic initiatives
  9.1.14 FluroTech Ltd.
    9.1.14.1 Company overview
    9.1.14.2 Financial performance
    9.1.14.3 Product benchmarking
    9.1.14.4 Strategic initiatives

LIST OF TABLES

Table 1 Scenarios considered for the 2020 potential market of Fluorescence-labeled antigen/antibodies testing in the U.S. and Canada
Table 2 Amusement and water parks in the U.S.
Table 3 Food & beverage manufacturing establishments in the U.S.
Table 4 Potential market share, by technology (Scenario C), 2020 (%)
Table 5 Competitive products analysis
Table 6 Competitive Analysis- COVID-19 POC Testing
Table 7 Saliva-based COVID testing product approval & timeline
Table 8 A list of Canadian universities and colleges
Table 9 Summary of studies pertaining to COVID-19 detection using CRISPR technology
Table 10 North America COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 11 North America COVID-19 saliva screening test potential market estimates & forecast, by travel stations, 2020 - 2023 (USD Million)
Table 12 North America COVID-19 saliva screening test potential market estimates & forecast, by factories, 2020 - 2023 (USD Million)
Table 13 North America COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 14 North America COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
Table 15 U.S. COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 16 U.S. COVID-19 saliva screening test potential market estimates & forecast, by travel stations, 2020 - 2023 (USD Million)
Table 17 U.S. COVID-19 saliva screening test potential market estimates & forecast, by factories, 2020 - 2023 (USD Million)
Table 18 U.S. COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 19 U.S. COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
Table 20 Canada COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 21 Canada COVID-19 saliva screening test potential market estimates & forecast, by travel stations, 2020 - 2023 (USD Million)
Table 22 Canada COVID-19 saliva screening test potential market estimates & forecast, by factories, 2020 - 2023 (USD Million)
Table 23 Canada COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 24 Canada COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
Table 25 Europe COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 26 Europe COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 27 Europe COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
Table 28 Asia Pacific COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 29 Asia Pacific COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 30 Asia Pacific. COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
Table 31 Rest of World COVID-19 saliva screening test potential market estimates & forecast, by location, 2020 - 2023 (USD Million)
Table 32 Rest of World COVID-19 saliva screening test potential market estimates & forecast, by technology, 2020 - 2023 (USD Million)
Table 33 Rest of World COVID-19 saliva screening test potential market estimates & forecast, by mode, 2020 - 2023 (USD Million)
LIST OF FIGURES

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Model details
Fig. 9 Top 10 U.S. Airlines, by Domestic Scheduled Enplanements, 2019 vs. 2020
Fig. 10 Weekly container ship port calls, Global, 2019 vs. 2020
Fig. 11 Impact of COVID-19 on international passenger traffic (all locations)
Fig. 12 Impact of COVID-19 on domestic passenger traffic (all locations)
Fig. 13 Passenger entries, exits, &interchanges at key railway stations in Great Britain, 2020 (% change from 2019)
Fig. 14 NFL games, 2020: Statistics
Fig. 15 Number of shopping malls & centers in North America, by region
Fig. 16 Number stores in shopping malls & centers in North America, by store type
Fig. 17 Operational mode of major universities & colleges in the U.S. (Post-COVID)
Fig. 18 Laboratory-confirmed COVID-19 cases among workers in meat and poultry processing facilities and food manufacturing and agriculture workplaces in the U.S.
Fig. 19 Preparedness of the food & beverage industry against COVID-19
Fig. 20 Market Segmentation
Fig. 21 Scenario A: Potential Market Size for Fluorescence-labeled antigen/antibodies testing, North America, 2020 (USD Million)
Fig. 22 Scenario B: Potential Market Size for Fluorescence-labeled antigen/antibodies testing, North America, 2020 (USD Million)
Fig. 23 Scenario C: Potential Market Size for Fluorescence-labeled antigen/antibodies testing, North America, 2020 (USD Million)
Fig. 24 Market driver relevance analysis (Current & future impact)
Fig. 25 Advantages of using saliva as a diagnostic specimen
Fig. 26 Market restraint relevance analysis (Current & future impact)
Fig. 27 Validated sample types for COVID-19 testing
Fig. 28 Global swab-based COVID-19 diagnostics market, 2020 - 2027 (USD million)
Fig. 29 Currently available test format for COVID-19 testing
Fig. 30 Currently available assay target for COVID-19 testing
Fig. 31 Strategy framework
Fig. 32 Company participant categorization
Fig. 33 Number of U.S. airports analyzed, by state
Fig. 34 COVID-19 saliva screening potential market (U.S. & Canada): Location movement analysis
Fig. 35 Domestic and international airline travel on the U.S. and foreign airlines
Fig. 36 World passenger traffic evolution at times of crisis/disease outbreak
Fig. 37 Total system (domestic and international) scheduled enplanements on the U.S. and foreign airlines
Fig. 38 Top 10 U.S. Airports, ranked by 2020 Domestic Scheduled Enplanements
Fig. 39 Canadian air passenger traffic from 2015 - 2019
Fig. 40 Alaska cruise statistics, 2016 - 2017
Fig. 41 Canada cruise industry, 2019
Fig. 42 Passenger Volume by Region 2019 (Tens of Thousands), 2019
Fig. 43 Value of U.S.-International Freight Flow Transported by Vessel: January 2019-October 2020 in billion
Fig. 44 Rail passenger traffic in the U.S. (2006 - 2019) (in billion passenger-kilometers)
Fig. 45 The list of American and Canadian football leagues.
Fig. 46 Change from pre-pandemic habits to planned post-pandemic habits in Canadian shoppers
Fig. 47 Mall traffic in 2020 in the U.S.
Fig. 48 America's Most-Visited Shopping Malls, 2011
Fig. 49 Theme park reopening in the U.S.
Fig. 50 Amusement park reopening models
Fig. 51 California state restrictions
Fig. 52 Steps taken by companies to tackle COVID-19 challenges
Fig. 53 Industry preparedness survey
Fig. 54 The U.S. meat and poultry industry, 2017 (USD million)
Fig. 55 The employment growth for pharmaceutical and medicine manufacturing from 2008 - 2020
Fig. 56 The number of employees in the U.S. biopharmaceutical industry by subsector in 2017
Fig. 57 Top 10 US-based mining companies as of July 2020
Fig. 58 COVID-19 impact on mining and metal companies
Fig. 59 Employment growth rate for Warehousing and Storage, 2008 - 2020
Fig. 60 Total number of warehouses in the U.S. from 2007 - 2019
Fig. 61 Top 20 warehouses in North America as of 2018
Fig. 62 COVID-19 saliva screening potential market (Other regions): Location outlook key takeaways
Fig. 63 COVID-19 saliva screening potential market (Other regions): Location movement analysis
Fig. 64 Number of international passengers, by region in million
Fig. 65 Busiest railway stations in Asia and Europe
Fig. 66 COVID-19 impact on Cruise community
Fig. 67 Top theme parks (other regions) by value and attendance
Fig. 68 Average number of visitors in shopping malls in Italy in 2016 in million
Fig. 69 Measures Taken By U.K. Universities Against COVID-19
Fig. 70 Student numbers in the U.K.’s higher education (2018 - 19)
Fig. 71 COVID-19 saliva screening market: Technology outlook key takeaways
Fig. 72 COVID-19 saliva screening market: Technology movement analysis
Fig. 73 Feluda COVID-19 test kit
Fig. 74 Sherlock-based COVID-19 test
Fig. 75 COVID-19 saliva screening test potential market: Mode outlook key takeaways
Fig. 76 COVID-19 saliva screening test potential market: Mode movement analysis
Fig. 77 Impact of COVID-19 on passenger traffic and aviation revenue in 2020, by region (as compared to 2019)
Fig. 78 COVID-19 saliva screening test potential market: Regional movement analysis


More Publications